Poliner L S, Tornambe P E, Michelson P E, Heitzmann J G
Department of Ophthalmology, University of California, San Diego.
Ophthalmology. 1993 Sep;100(9):1417-24. doi: 10.1016/s0161-6420(93)31467-3.
The current study is a prospective randomized clinical trial to determine the effect of interferon alpha-2a on eyes with subfoveal subretinal neovascularization secondary to age-related macular degeneration (AMD).
Twenty eyes of 19 patients with subfoveal neovascularization secondary to AMD were prospectively evaluated. Ten eyes were randomized to subcutaneous interferon alpha-2a (3 million units/m2) every other day for 8 weeks, whereas 10 eyes were randomized to observation alone as controls. Fluorescein angiography, best-corrected visual acuity tests, and macular visual field assessments were performed, and all eyes were followed for a minimum of 6 months.
At the 2-month follow-up visit, the interferon group manifested somewhat slower neovascular growth than controls, but the results were not statistically significant. At the 6-month follow-up visit, there was no difference in visual acuity, average macular sensitivities, or extent of neovascularization. The rate of neovascular progression was significantly related to the extent of previous macular photocoagulation in both groups.
Though the rate of neovascular progression was slowed during the second month of interferon treatment, the effect did not persist once interferon was discontinued. No long-term benefit appeared to be present. Unfortunately, lengthening the time of administration, increasing the dosage, or increasing the frequency of administration would likely give rise to unacceptable side effects.
本研究是一项前瞻性随机临床试验，旨在确定干扰素α-2a对年龄相关性黄斑变性（AMD）继发的黄斑下视网膜下新生血管形成的眼睛的影响。
对19例AMD继发黄斑下新生血管形成患者的20只眼睛进行前瞻性评估。10只眼睛被随机分配接受皮下注射干扰素α-2a（300万单位/m²），隔日一次，共8周，而10只眼睛被随机分配仅作为对照进行观察。进行了荧光素血管造影、最佳矫正视力测试和黄斑视野评估，所有眼睛至少随访6个月。
在2个月的随访中，干扰素组新生血管生长比对照组稍慢，但结果无统计学意义。在6个月的随访中，视力、平均黄斑敏感度或新生血管形成范围无差异。两组新生血管进展率均与既往黄斑光凝范围显著相关。
虽然在干扰素治疗的第二个月新生血管进展率有所减慢，但一旦停止使用干扰素，这种效果就不会持续。似乎没有长期益处。不幸的是，延长给药时间、增加剂量或增加给药频率可能会产生不可接受的副作用。
